Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514509 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories
A Phase 4 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 370
- Enrollment target
NCT05514509 is a Phase 4 study that has completed, run by ViiV Healthcare. The registered enrollment target is 370 participants.
The verdict
NCT05514509, a Phase 4 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 370 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP). The study objectives are also to identify barriers and facilitators to implementation. The first of two participant types in the study are the Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available CAB PrEP via prescription from the PrEP provider. The second are Staff Study Participants (SSPs) who are site staff involved in the administrative and clinical aspects of offering and administering PrEP to PSPs at the clinical site.
Interventions
- DRUG APRETUDE
- DRUG Cabotegravir tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2022-10-28 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05514509
The ClinicalTrials.gov registry entry for NCT05514509 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which APRETUDE is the first listed.
NCT05514509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05514509 about?
NCT05514509 is a clinical study titled "A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories". The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP). The study objectives are also to identify barriers and facilitators to implementation. The first of two...
What is the current status of trial NCT05514509?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 370 participants. The study started on 2022-10-28. Estimated completion is 2025-09-02.
What interventions are being tested in trial NCT05514509?
The interventions under investigation include: APRETUDE (DRUG), Cabotegravir tablet (DRUG).
Who is sponsoring clinical trial NCT05514509?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.